September 12, 2019 / 10:16 AM / 2 months ago

Tocagen's brain cancer treatment fails late-stage study

Sept 12 (Reuters) - Tocagen Inc said on Thursday its experimental treatment did not prove effective in helping patients with a type of brain cancer to live longer, in a late-stage study.

The California-based company said in the trial its lead product candidate Toca 511 & Toca FC also did not show meaningful superiority in secondary goals compared to standard of care treatment. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below